Microbicide Trials Network

MTN-020

Details

Protocol Title: 
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women
DAIDS Protocol ID: 
11840
Status: 
Enrolling

Protocol Chair(s)

Jared Baeten (Protocol Chair)
Thesla Palanee (Protocol Co-Chair)

Description

ASPIREA Study to Prevent Infection with a Ring for Extended Use, also known as MTN-020, is a Phase III study that seeks to determine whether a woman’s use of a vaginal ring containing the antiretroviral (ARV) drug dapivirine is a safe and effective method for protecting against HIV infection. The study will enroll approximately 3,476 women at several sites in Africa beginning mid 2012 and take approximately two years to conduct, with results anticipated late 2014 or early 2015.

Other Study Info

Sponsors:
Division of AIDS, US National Institute of Allergy and Infectious Diseases

US National Institutes of Health

Co-Sponsors:
IPM

Study Design:
Phase 3, multi-site, two-arm, randomized (1:1), double-blind, placebo controlled trial